Alpha 2.0
Login Register
» Authors » C Sickles

C Sickles

Explore the profile of C Sickles including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 161
Followers 0
Related Specialties
General Medicine
Oncology
General Surgery
Top 10 Co-Authors
E A Stadtmauer
D L Porter
S M Luger
P A Mangan
A Cesano
D Santoli
D E Tsai
H C Moore
D A Leung
I Brodsky
Published In
Prog Clin Biol Res
Clin Cancer Res
Ann Oncol
J Vasc Interv Radiol
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease
Cohen A, Luger S, Sickles C, Mangan P, Porter D, Schuster S, et al.
Bone Marrow Transplant . 2002 Jul; 30(1):23-8. PMID: 12105773
Gemtuzumab ozogamicin (GO) (Mylotarg, CMA-676) is a novel chemotherapeutic agent consisting of an anti-CD33 monoclonal antibody linked to calicheamicin, and is associated with a 30% response rate in patients with...
2.
Determinants of postembolization syndrome after hepatic chemoembolization
Leung D, Goin J, Sickles C, Raskay B, Soulen M
J Vasc Interv Radiol . 2001 Apr; 12(3):321-6. PMID: 11287509
Purpose: Postembolization syndrome (PES) occurs in the majority of patients undergoing hepatic chemoembolization, and is the major reason for hospitalization after the procedure. The ability to identify which groups of...
3.
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer
Visonneau S, Cesano A, Porter D, Luger S, Schuchter L, Kamoun M, et al.
Clin Cancer Res . 2000 May; 6(5):1744-54. PMID: 10815893
The human cytotoxic T-cell line TALL-104 displays antitumor effects in animals with implanted and spontaneous malignancies. A Phase I trial was conducted to determine toxicity of TALL-104 cell therapy in...
4.
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group
Stadtmauer E, ONeill A, Goldstein L, Crilley P, Mangan K, Ingle J, et al.
N Engl J Med . 2000 Apr; 342(15):1069-76. PMID: 10760307
Background: We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-dose chemotherapy in women with metastatic breast cancer....
5.
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy
Moore H, Mick R, Solin L, Sickles C, Mangan P, Luger S, et al.
Ann Oncol . 1999 Oct; 10(8):929-36. PMID: 10509154
Background: High-dose chemotherapy with autologous stem-cell transplantation is used increasingly in the treatment of poor-prognosis primary breast cancer. Because these patients may be cured with standard multimodality therapy, it is...
6.
High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer
Stadtmauer E, Hodi F, Sickles C, Biggs D, Mangan P, Buzby G, et al.
Prog Clin Biol Res . 1994 Jan; 389:487-95. PMID: 7535458
No abstract available.